Compare TGT & ALC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TGT | ALC |
|---|---|---|
| Founded | 1902 | 1945 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Department/Specialty Retail Stores | Ophthalmic Goods |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 43.7B | 39.0B |
| IPO Year | N/A | N/A |
| Metric | TGT | ALC |
|---|---|---|
| Price | $110.85 | $79.28 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 27 | 12 |
| Target Price | ★ $101.08 | $88.29 |
| AVG Volume (30 Days) | ★ 7.0M | 1.2M |
| Earning Date | 03-03-2026 | 02-24-2026 |
| Dividend Yield | ★ 4.10% | 0.27% |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 8.25 | 2.10 |
| Revenue | ★ $105,242,000,000.00 | $10,185,000,000.00 |
| Revenue This Year | N/A | $5.76 |
| Revenue Next Year | $1.80 | $7.24 |
| P/E Ratio | ★ $13.48 | $37.39 |
| Revenue Growth | N/A | ★ 4.34 |
| 52 Week Low | $83.44 | $71.55 |
| 52 Week High | $145.08 | $99.20 |
| Indicator | TGT | ALC |
|---|---|---|
| Relative Strength Index (RSI) | 77.02 | 48.52 |
| Support Level | $103.16 | $78.78 |
| Resistance Level | $111.86 | $81.65 |
| Average True Range (ATR) | 2.84 | 1.54 |
| MACD | 0.80 | -0.18 |
| Stochastic Oscillator | 93.04 | 44.10 |
Target's start dates back to 1962, but now it is one of the largest discount retailers in the United States (where it derives all of its sales), operating just under 2,000 stores and generating over $106 billion in fiscal 2024 sales. The company offers a broad assortment of merchandise across categories including apparel and accessories (16% of fiscal 2024 revenue), beauty and household essentials (30%), food and beverage (23%), hardlines (15%), as well as home furnishings (16%). Target's model is anchored in its physical store base, which fulfills more than 97% of sales. Around 30% of sales are derived from its own private-label brands.
Alcon is one of the leading visioncare companies in the world. Following nine years as a Novartis subsidiary, it was spun off as a public company in April 2019. Alcon operates in two segments: visioncare and surgical. Visioncare comprises contact lenses, lenscare solutions, and a suite of ocular health products. With brands like Dailies, Total1, and Air Optix, Alcon controls about one fourth of the US contact lens market. Surgical comprises intraocular lenses, ophthalmic surgical equipment, and consumables used during surgeries. Its main products include Centurion, a phacoemulsification device used during cataract surgeries, and a portfolio of IOLs including PanOptix and Vivity. Alcon has one of the largest installed bases of eye surgical equipment in the world.